Full-Time

Assistant Scientist

Vaccines, Dry Lab/Data Review

Posted on 8/21/2026

Deadline 8/27/26
Thermo Fisher Scientific

Thermo Fisher Scientific

10,001+ employees

Supplies laboratory instruments, reagents, diagnostics

Compensation Overview

$21 - $21.63/hr

+ Variable annual bonus

No H1B Sponsorship

Richmond, VA, USA

In Person

Relocation assistance is not provided; relocation costs are the candidate’s responsibility.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Requirements
  • A bachelor's degree or equivalent and relevant formal academic or vocational qualification.
  • Previous experience comparable to 0 to 1 years that provides the knowledge, skills, and abilities to perform the job.
  • Knowledge of routine operation, maintenance, and theory of analytical instrumentation, standard operating procedures, and regulatory guidelines.
  • Knowledge of applicable regulatory authorities, compendia, and International Council for Harmonisation guidelines.
  • Excellent manual dexterity skills.
  • Good written and oral communication skills.
  • Time management and project management skills.
  • Proven problem-solving and troubleshooting abilities.
  • Ability to cross-train on sample preparation techniques with another laboratory group.
  • Ability to work in a collaborative work environment with a team.
  • Ability to work in a laboratory and/or clinical environment with exposure to electrical office equipment, biological fluids, infectious organisms, irritants, radiation, toxic materials, hazardous waste, fluctuating temperatures, and required personal protective equipment.
  • Ability to work upright and/or stationary for 6–8 hours per day, perform repetitive hand movements to operate laboratory equipment, and occasionally crouch, stoop, bend, twist, lift, and carry up to 15–20 pounds.
  • Ability to access and use in-house and off-the-shelf computer software.
  • Ability to communicate and understand information presented through spoken words and sentences.
  • Ability to work independently with little guidance, plan work schedules to meet goals, maintain concentration, multitask, and perform under changing conditions and stress.
  • Regular and consistent attendance.
Responsibilities
  • Perform laboratory work in accordance with client protocols, methods, and requirements.
  • Prepare study protocols, project status reports, final study reports, and other project-related technical documentation.
  • Design experimental studies and participate in technical troubleshooting.
  • Review, interpret, and analyze data for technical quality and compliance with protocols, methods, and standard operating procedures.
  • Review laboratory investigations and deviations.
  • Organize, schedule, and supervise laboratory resources for group project activities and update project status.
  • Respond to client questions and needs, coordinate client communication, and record meeting minutes.
  • Assist group leaders in their responsibilities.
  • Assist in the preparation and implementation of PPD and client standard operating procedures and company operational policies.
  • Ensure adherence to standard operating procedures, safety standards, and company policies.
  • Occasionally drive to site locations and travel domestically.
Thermo Fisher Scientific

Thermo Fisher Scientific

View

Thermo Fisher Scientific provides life sciences tools and services for research, healthcare, and industry. Its products include laboratory instruments, reagents, consumables, and software for activities like protein biology, PCR, sequencing, and bioprocessing. It differentiates itself with an end-to-end footprint across trusted brands and strong customer support and education, plus direct sales and promotions. Its goal is to help make the world healthier, cleaner, and safer by enabling discovery, diagnostics, and quality manufacturing across research institutions, healthcare providers, and government bodies.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $11.99 billion, up 10%, with adjusted EPS up 13%.
  • August 11 PPMI proteomics covered 5,500 samples, deepening Thermo Fisher's precision-medicine credibility.
  • Reuters on August 10 cited 15%-20% India customer growth over five years.

What critics are saying

  • CVE-2026-17583 lets attackers alter Applied Biosystems DNA files; forensic customers face trust damage.
  • Franklin closes December 31, 2026, and Weaverville cuts 421 jobs through 2027.
  • Microbiology divestiture and end-of-life product lines expose Thermo Fisher to execution and replacement risk.

What makes Thermo Fisher Scientific unique

  • Thermo Fisher's July 2026 guidance hike showed broad demand across pharma, biotech, and diagnostics.
  • Hyderabad's CEC and BDC give customers hands-on workflow training and co-development.
  • January 2026 NVIDIA collaboration ties instruments, software, and AI-enabled laboratory automation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Fertility Treatment Support

Family Planning Benefits

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Company News

Advance Media Group
Aug 19th, 2026
Where biopharma technology meets practice: inside Thermo Fisher Scientific's Customer Experience Centre in Hyderabad.

Where biopharma technology meets practice: inside Thermo Fisher Scientific's Customer Experience Centre in Hyderabad. India's biopharmaceutical industry is entering a phase in which the growing complexity of scientific innovation is redefining what the ecosystem needs from technology. With the expansion of biologics, biosimilars, peptides, proteins, oligonucleotides and other advanced India's biopharmaceutical industry is entering a phase in which the growing complexity of scientific innovation is redefining what the ecosystem needs from technology. With the expansion of biologics, biosimilars, peptides, proteins, oligonucleotides and other advanced therapeutic modalities, sophisticated analytical platforms are becoming increasingly important. Yet access to technology alone cannot close the capability gap; the greater challenge is enabling scientists and industry to understand, evaluate and effectively apply these technologies within real development and manufacturing workflows. This context was evident at the BIOPHARMA Summit 2026, powered by Orbitrap and Vanquish, held on August 6-7 in Hyderabad under the theme "Advancing innovation, technology and collaboration." While the summit brought together scientific and industry stakeholders, the Thermo Fisher Scientific's Customer Experience Centre (CEC) and Bioprocess Design Centre (BDC) in Hyderabad offered a closer perspective on how technology infrastructure can contribute to India's next stage of biopharmaceutical growth. The significance of the CEC lies in what it enables. The facility provides customers and researchers with direct access to advanced technologies, workflows and application expertise, allowing them to evaluate platforms, gain hands-on experience, and receive technical training and work with Thermo Fisher experts on real-world scientific and manufacturing challenges. Rather than functioning solely as a demonstration facility, the CEC creates an environment where technology can be assessed against practical requirements and where the gap between technical capability and real-world application can be narrowed. This becomes particularly important as biopharmaceutical development grows more analytically demanding. Complex biological molecules generate increasingly sophisticated datasets and require precise decisions around molecular characterization, impurities, structure and process performance. The critical question is therefore not merely whether a laboratory has access to an advanced instrument, but whether its scientific teams can deploy it effectively, interpret the resulting information and translate it into meaningful development decisions. The BDC complements this capability by bringing a bioprocessing dimension to the Hyderabad ecosystem, supporting engagement across the biopharmaceutical lifecycle from research and development through commercialization. Thermo Fisher has identified three priorities for strengthening India's life-sciences ecosystem: greater access to world-class technologies, talent development, and improved productivity and time-to-market. The talent dimension is particularly important. India has a strong scientific base, but continued progress requires closer connections between education, research, technology and industry. Thermo Fisher's capability-building approach includes approximately 10 partnerships with academic institutions, research organizations and government agencies, including IIT Guwahati, KIIT Odisha, the Atal Incubation Centre and C-CAMP, among others. Such collaborations provide scientists, researchers and industry professionals with practical exposure to advanced technologies and workflows. The new technologies introduced at the summit further demonstrate this evolution. Thermo Fisher announced the Orbitrap Excedion Mass Spectrometer and Vanquish Amplify UHPLC system. Orbitrap Excedion supports the characterization of complex molecules including proteins, peptides and oligonucleotides, while Vanquish Amplify strengthens analytical capabilities for pharmaceutical research and development. Importantly, the launches were supported by workflow demonstrations and guidance on data analysis and interpretation, highlighting that advanced instrumentation delivers greater value when technology is connected to scientific expertise. Artificial Intelligence adds another dimension. Thermo Fisher outlined an enterprise-wide AI strategy covering operational efficiency, AI-enabled products and services, and customer experience, with AI increasingly being used to convert complex datasets into meaningful insights and support faster scientific decision-making. During the media roundtable held alongside the summit, Thermo Fisher leadership also discussed the evolving relationship between technology providers and customers. Customer engagement was described as a two-way learning process, with feedback informing product development, localization strategies and investment priorities. The broader ambition is to move beyond supplying products towards becoming a long-term strategic partner and trusted advisor. For India, this approach has wider significance. The country's biopharmaceutical opportunity will require more than sophisticated platforms; it will require an ecosystem capable of absorbing technology, developing expertise, adapting it to local requirements and translating scientific capability into faster and more effective development. The Hyderabad CEC offers one example of this emerging model. Its value lies not simply in the instruments it houses, but in bringing technology, people, expertise and practical application together. As India moves towards high-value biologics and advanced therapeutic development, such connections could become increasingly important. Ultimately, the future of Indian biopharma will depend on how effectively technology can move from laboratory capability to scientific knowledge, from knowledge to innovation, and from innovation to patient impact. The CEC represents an important step in that direction - not simply showing scientists what technology can do, but helping them understand what they can do with it.

BioSpectrum India
Aug 15th, 2026
Thermo Fisher launches Vanquish(TM) Amplify UHPLC system and Orbitrap(TM) Excedion(TM) mass spectrometer in India.

Thermo Fisher launches Vanquish(TM) Amplify UHPLC system and Orbitrap(TM) Excedion(TM) mass spectrometer in India. August 15, 2026 | Saturday | News Products launched at the Biopharma Summit 2026 in Hyderabad. At the recently held Biopharma Summit 2026 in Hyderabad, Thermo Fisher unveiled innovative products for the Indian researchers and scientific community. A highlight of the day was the launch of the Thermo Scientific(TM) Orbitrap(TM) Excedion(TM) mass spectrometer, marking an exciting step forward in next-generation biotherapeutic characterisation. Powered by industry-leading high-resolution accurate-mass (HRAM) technology, the Orbitrap Excedion is designed to help scientists tackle increasingly complex modalities and generate deeper insights, supporting confident decisions across the biopharma development journey. Another highlight was the launch of the Thermo Scientific(TM) Vanquish(TM) Amplify UHPLC system, alongside the new Thermo Scientific(TM) SurePac(TM) Oligo RP MDi(TM) and SurePac(TM) Protein RP MDi(TM) columns, designed to bring greater confidence and performance to complex biopharma workflows. During an exclusive interaction with selected media, Srinath Venkatesh, Managing Director, India and South Asia, Thermo Fisher Scientific said, "These products have already been launched globally, and now we are bringing them to India in response to customer needs. As the industry moves towards large molecules, there is a great deal of work happening on complex therapeutics, especially oligonucleotides, peptides, proteins, and other complex biologics. The Excedion is specifically designed for those applications." "Our focus is not just on launching the product, but also on ensuring customers receive the training they need, including data interpretation and data analysis. This summit is about demonstrating how data generated by these instruments is analysed, and we will continue doing that through smaller training sessions with scientists so that we can provide access to all of them", he further said. Sharing his thoughts on the objective behind organising the Biopharma Summit, Venkatesh said, "This is the second in the series. Last year, BioSpectrum India organised what BioSpectrum India called the Orbitrap Summit. This year, BioSpectrum India has expanded it into the BioPharma Summit. Last year it was held in Bengaluru. This year it is in Hyderabad. Based on how BioSpectrum India see it today, this is going to become an annual feature. Tony Acciarito, President, APMEA, Thermo Fisher Scientific said "The feedback from customers last year was very positive. That's why the team believes this is a great forum to continue building on. As we learn more about what works and what doesn't, we will continue to refine and expand it." The Biopharma Summit 2026 also included a detailed tour of the company's Customer Experience Centre (CEC), at the Genome Valley in Hyderabad. With a combined investment of Rs 85-90 crore in CEC and the Bioprocess Design Centre (BDC), in Hyderabad's Genome Valley, Thermo Fisher is building on its investments and growing presence in India. "The Customer Experience Centre and the Bioprocess Design Centre were established in response to what our customers asked for. Our customers and stakeholders clearly told us they wanted access to world-class technology here in India so that researchers could experience it firsthand. They also wanted a partner they could co-create with. Customers also asked us to help solve challenges around productivity and time to market. I think our differentiation lies in responding directly to what our customers are asking us to do. From a talent perspective, we have built partnerships with many of the country's leading academic institutions. Our objective is to integrate all of these into an ecosystem where we can help develop the new talent the industry requires and ensure they acquire these skills", said Venkatesh. Tony Acciarito further mentioned, "The day we stop listening to our customers and start focusing on being better than our competition is the day we will fail. If our competitors are building similar capabilities, then congratulations to them. More capability on the ground is a positive outcome, regardless of who provides it. For us, the priority is staying very close to our customers." Dr Manbeena Chawla

VIR
Aug 13th, 2026
NIC and Thermo Fisher advance shared tech infrastructure.

NIC and Thermo Fisher advance shared tech infrastructure. The National Innovation Centre (NIC) and Thermo Fisher Scientific held a forum on advancing Vietnam's semiconductor, AI, and innovation ambitions on August 13. The event brought together representatives from government agencies, experts, businesses, research institutes, universities and partners in semiconductors, AI, biomedical technology and innovation to discuss cooperation opportunities, promote shared research infrastructure and strengthen Vietnam's innovation ecosystem. | Photo: NIC | Recognising shared research and technology infrastructure as a key impediment in the development of strategic technology industries, the NIC has stepped up cooperation with Thermo Fisher Scientific, a global technology group specialising in life sciences, research, analytical technologies and solutions for a range of high-tech industries. During his visit to Vietnam, Gianluca Pettiti, president and COO, and president of Life Sciences Solutions at Thermo Fisher Scientific, attended the forum and discussed cooperation potential with the NIC and Vietnamese partners, particularly in developing scientific and technological infrastructure and shared research models. The partnership between NIC and Thermo Fisher aims to bring advanced international infrastructure, equipment, technologies and expertise closer to Vietnamese businesses, startups, research institutes and universities. This is expected to reduce technology access costs, shorten research and product development timelines, and strengthen domestic innovation capacity. Pettiti said, "Vietnam has significant opportunities to develop high-tech industries and needs continued investment in research infrastructure, technology, human resources and stronger links between research and businesses." Thermo Fisher Scientific aims to contribute its technology, equipment and expertise to help Vietnam strengthen research, product development and innovation capabilities. "Connecting the company's technological capabilities, equipment and expertise with Vietnamese government agencies, universities, research institutes and businesses will expand access to advanced technologies, accelerate their application and help bring research outcomes into practice," he added. Speaking at the forum, Vo Xuan Hoai, deputy director of NIC, said, "The greatest value of the cooperation between NIC and Thermo Fisher lies in jointly building an open research infrastructure model where businesses, startups, universities and research institutes can access internationally standardised technologies, equipment and expertise at more reasonable costs and within shorter timeframes." Under the cooperation framework, a shared laboratory at NIC Hoa Lac will serve as foundational infrastructure for research, product development, technology testing and workforce training. NIC will work with Thermo Fisher to develop an implementation roadmap while connecting businesses, startups, research institutes and universities that need access to the infrastructure. The two sides will also promote training and capacity-building programmes and mobilise additional technology corporations, research organisations and international partners to participate. Through the initiative, NIC aims to establish an internationally standardised model of shared research and innovation infrastructure at Hoa Lac High-Tech Park, enabling domestic and international technology resources to be used more effectively and potentially replicated in other strategic technology fields. | MoU signing ceremony between NIC and Thermo Fisher Scientific. Photo: NIC | The forum featured a panel discussion on developing shared infrastructure for semiconductors, AI, and biomedical technology, with the participation of Dan Kritenbrink, former US Ambassador to Vietnam, representatives from Thermo Fisher Scientific, relevant agencies, Hanoi Industrial Park Management Board, Hanoi University of Science and Technology, and Vietnam National University, also in Hanoi. During the forum, NIC and Thermo Fisher Scientific signed a MoU, marking a new step in their cooperation to support Vietnam's innovation ecosystem through shared science and technology infrastructure and stronger public-private cooperation in strategic technology fields. Under the cooperation framework, Thermo Fisher is expected to work with the NIC to develop an internationally standardised shared laboratory for semiconductor and biomedical technologies at NIC Hoa Lac. The infrastructure will serve businesses, startups, research institutes and universities while enabling Vietnamese organisations to access international technologies, equipment and expertise. For the NIC, the MoU represents an initial step towards developing a new public-private cooperation model for technology infrastructure. Under this model, the state will play a role in enabling and connecting resources; international technology companies will contribute technologies and expertise; while businesses, research institutes, and universities will directly utilise the infrastructure, develop technologies, and commercialise research results. Through its cooperation with Thermo Fisher Scientific, the NIC is reinforcing its role as a national hub connecting technology resources, expertise, infrastructure and the domestic market with leading global technology corporations.

Boston Cambridge Biotech Networks
Aug 11th, 2026
Thermo Fisher Scientific collaborates with The Michael J. Fox Foundation to advance proteomics-enabled Parkinson's Precision Medicine.

Thermo Fisher Scientific collaborates with The Michael J. Fox Foundation to advance proteomics-enabled Parkinson's Precision Medicine. August 11, 2026 BCBN news, syndication comments off on thermo Fisher Scientific collaborates with The Michael J. Fox Foundation to advance proteomics-enabled Parkinson's Precision Medicine. WALTHAM, Mass.-(BUSINESS WIRE)-Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation's (MJFF) landmark study, the Parkinson's Precision Medicine Initiative (PPMI). The resulting data are now in PPMI's data repository, where they are available to the global research community. The project creates a large-scale proteomics resource designe Click here to view original post

WebWire
Aug 11th, 2026
XPO appoints Jonas Svedlund as chief legal officer.

XPO appoints Jonas Svedlund as chief legal officer. Greenwich, Conn. - WEBWIRE - Tuesday, August 11, 2026 XPO (NYSE: XPO), a leading provider of freight transportation in North America, announced that Jonas Svedlund has joined the company as chief legal officer, effective immediately. He will lead the company's legal and compliance functions, including corporate governance and commercial matters. Mario Harik, chairman and chief executive officer of XPO, said, "Jonas is an accomplished executive who will help advance our strategic priorities. He brings deep legal expertise and a proven ability to partner with organizational leaders at every level. He is an excellent addition to our leadership team and I'm pleased to welcome him to XPO." Svedlund most recently served as deputy general counsel for Thermo Fisher Scientific, where he oversaw the company's corporate and commercial legal functions. Earlier, he held various executive roles during more than a decade with General Electric, including serving as general counsel for two separate GE businesses. He began his career as a corporate attorney with Sullivan & Cromwell. Svedlund holds a juris doctor degree from Harvard Law School and a bachelor's degree from the University of California, Berkeley. About XPO XPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company's customer-focused organization efficiently moves 16 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 586 locations and 38,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn, Facebook, X, Instagram and YouTube. WebWireID358731 This news content was configured by WebWire editorial staff. Linking is permitted. Distribute your news. * Every day, hundreds of individuals and companies choose WebWire to distribute their news. * WebWire places your news within numerous highly trafficked news search engines generating leads and publicity. * Submit Your Release Now!